IP Library Granted Patent US 8,273,790
Granted Patent B2
US 8,273,790 · App. 13/370,768 · Granted Sep 25, 2012

Exo-selective synthesis of himbacine analogs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,273,790
App. No.
13/370,768
Granted
Sep 25, 2012
Kind
B2
Abstract

This application discloses a novel process for the synthesis of himbacine analogs, as well as the compounds produced thereby. The synthesis proceeds by alternative routes including the cyclic ketal amide route, the chiral carbamate amide route, and the chiral carbamate ester route. The compounds produced thereby are useful as thrombin receptor antagonists. The chemistry disclosed herein is exemplified in the following synthesis sequence:

Claims (19)

1. A process of preparing a compound of the formula

comprising:

converting Compound 9:

to Compound 10:

and converting Compound 10 to Compound 8

wherein R 15 and R 16 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, alkylaryl, arylalkyl, and heteroaryl groups or, when taken together with the nitrogen to which they are attached, may form a 3- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms.

2. The process of claim 1 , wherein Compound 10 is converted to Compound 8 by:

(a) reducing Compound 10 to Compound 11:

and,

(b) reacting Compound 11 with Compound 12:

to yield Compound 8.

3. The process of claim 1 , wherein Compound 10 is converted to Compound 8 by reacting Compound 10 with Compound 12 to yield Compound 13:

and reducing Compound 13 to yield Compound 8.

4. The process of claim 1 , wherein Compound 9 is converted to Compound 10 by a process selected from the group consisting of:

wherein:

P is a protecting group and X is a leaving group and is selected from the group consisting of Cl, Br, I, and heterocyclic rings;

L is a ligand and is selected from PR′ 3 wherein R′ is selected from the group consisting of alkyl, aryl, alkylaryl, and NR″, wherein R″ is selected from the group consisting of alkyl, aryl, and alkylaryl;

Y is selected from the group consisting of Cl, Br, I, and R′″COO, wherein R′″ is selected from the group consisting of alkyl, aryl, alkylaryl, and arylalkyl; and,

n ranges from 0 to 4.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2020
From: ARALEZ PHARMACEUTICALS TRADING DAC
To: TOPROL ACQUISITION LLC
Reel/Frame 054027/0047 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2020
From: TOPROL ACQUISITION LLC
To: XSPIRE PHARMA, LLC
Reel/Frame 053731/0376 →
RECEIVING PARTY/ASSIGNEE ADDRESS CHANGE FOR ASSIGNMENT RECORDED AT REEL/FRAME 039767/0695 Recorded Aug 31, 2018
From: MERCK SHARP & DOHME CORP.
To: ARALEZ PHARMACEUTICALS TRADING DAC
Reel/Frame 046989/0669 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY PREVIOUSLY RECORDED AT REEL: 046696 FRAME: 0772. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 30, 2018
From: ARALEZ PHARMACEUTICALS TRADING DESIGNATED ACTIVITY COMPANY
To: DEERFIELD MANAGEMENT COMPANY, L.P., AS ADMINISTRATIVE AGENT
Reel/Frame 046988/0741 →
SECURITY INTEREST Recorded Aug 24, 2018
From: ARALEZ PHARMACEUTICAL TRADING DAC
To: DEERFIELD MANAGEMENT COMPANY, L.P., AS ADMINISTRATIVE AGENT
Reel/Frame 046696/0772 →
SECURITY INTEREST Recorded Sep 29, 2016
From: ARALEZ PHARMACEUTICALS TRADING DAC
To: DEERFIELD PRIVATE DESIGN FUND III, L.P.; DEERFIELD INTERNATIONAL MASTER FUND, L.P.; DEERFIELD PARTNERS, L.P.
Reel/Frame 039892/0309 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2016
From: MERCK SHARP & DOHME CORP.
To: ARALEZ PHARMACEUTICALS TRADING DAC
Reel/Frame 039767/0695 →